Stock comparison
Haemonetics
Telix Pharmaceuticals Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
TLX
Telix Pharmaceuticals Limited
Market cap
$3.21B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | TLX | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 31F | HAE |
| Benjamin Graham | 85A | 49D | HAE |
| Philip Fisher | 60C | 50C | HAE |
| Peter Lynch | 54C | 29F | HAE |
| Joel Greenblatt | 31F | 0F | HAE |
| Charlie Munger | 54D | 44D | HAE |
| Terry Smith | 55D | 38D | HAE |
Side-by-side metrics
| Metric | HAE | TLX |
|---|---|---|
| Market cap | $2.98B | $3.21B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | 211.6x |
| ROIC (TTM) | 8.37% | 1.77% |
| Gross margin | 55.74% | 50.76% |
| Net margin | 7.29% | -0.89% |
| Revenue CAGR 5y | 7.65% | 2.55% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Net margin7.29%vs -0.89%+112%
- EV/EBIT14.1xvs 211.6x+93%
- ROIC (TTM)8.37%vs 1.77%+79%
- Gross margin55.74%vs 50.76%+9%
TLX leads on
- P/E (TTM)-vs 24.8x+105%
- Revenue CAGR 5y2.55%vs 7.65%+97%
- Debt / Equity1.3xvs 1.5x+18%
- Market cap$3.21Bvs $2.98B+7%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.